Episode 035: How Translational Science Can Solve Pharma's Productivity Puzzle

The infrastructure we rely on to create new medicines is in sore need of an upgrade. More and more investigational drugs are streaming into the pipeline. But most of them fail in clinical trials, draining corporate resources, disappointing investors, and shattering the hopes of patients. Financially speaking, return on investment (ROI) for R&D in biopharma is at an all-time low of 1.9%.In a recent article, Riaz Bandali, President, Early Phase Clinical Services and George Scott, Seni...